Update: 20 November 2020
WHO has issued a conditional recommendation against the use of remdesivir in hospitalized patients, regardless of disease severity, as there is currently no evidence that remdesivir improves survival and other outcomes in these patients.
This recommendation, released on 20 November, is part of a living guideline on clinical care for COVID-19. It was developed by an international guideline development group, which includes 28 clinical care experts, 4 patient-partners and one ethicist.
The guidelines were developed in collaboration with the non-profit Magic Evidence Ecosystem Foundation (MAGIC), which provided methodologic support. The guidelines are an innovation, matching scientific standards with the speed required to respond to an ongoing pandemic.
Work on this began on 15 October when the WHO Solidarity Trial published its interim results. Data reviewed by the panel included results from this trial, as well as 3 other randomized controlled trials. In all, data from over 7000 patients across the 4 trials were considered.
The evidence suggested no important effect on mortality, need for mechanical ventilation, time to clinical improvement, and other patient-important outcomes.
The guideline development group recognized that more research is needed, especially to provide higher certainty of evidence for specific groups of patients. They supported continued enrollment in trials evaluating remdesivir.
Updated 20 November 2020
* A conditional recommendation is issued when the evidence around the benefits and risks of an intervention are less certain. In this case, there is a conditional recommendation against the use of remdesivir. This means that there isn’t enough evidence to support its use.
- Statement on the fifth meeting of the International Health Regulations (2005) Emergency Committee regarding the COVID-19 pandemic
- Validation Protocol for COVID-19 Diagnostic Items, Nepal
- National Testing-Guidelines for COVID-19 (Version 5), Nepal
- The impact of COVID-19 on the TB epidemic: A community perspective
- List of Laboratories for COVID19 testing in Nepal
- The Global Burden of Disease Study 2019 #GBDstudy
- Nepal National Health Accounts 2018/19 and 2019/20
- Vaccine Preventable Diseases Surveillance Plan (Polio Transition Plan)
- Recommendations of Measles Outbreaks and Root Cause Analysis 2022-23
- Nepal restricts trans-fatty acids in food
- National Immunization Schedule, Nepal (Updated)
Thanks for visiting us.
Disclaimer: The resources, documents, guidelines, and information on this blog have been collected from various sources and are intended for informational purposes only. Information published on or through this website and affiliated social media channels does not represent the intention, plan, or strategies of an organization that the initiator is associated with in a professional or personal capacity, unless explicitly indicated.
If you have any complaints, information, or suggestions about the content published on Public Health Update, please feel free to contact us at email@example.com.